english.prescrire.org > Spotlight > 100 most recent > In the June issue of Prescrire International. Hydroxycarbamide: interstitial lung disease

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

In the June issue of Prescrire International. Hydroxycarbamide: interstitial lung disease

FREE DOWNLOAD Hydroxycarbamide, alias hydroxyurea, is a cytotoxic drug administered orally in some myeloproliferative syndromes, and to some patients with sickle cell disease to prevent acutely painful vaso-occlusive crises, acute chest syndrome and hospitalisation.
Full text available for free download.

Summary

  • Three French regional pharmacovigilance centres analysed 41 cases of non-infectious pulmonary disease attributed to hydroxycarbamide, recorded in the French pharmacovigilance database between 1988 and 2019.
     
  • Their analysis showed that onset occurred after a period varying from a few months to several years, and sometimes had a fatal outcome.

©Prescrire 1 June 2022

Source: "Hydroxycarbamide: interstitial lung disease" Prescrire International 2022; 31 (238): 160. Free.

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook Share on Twitter

Read more:

All the subjects in
Prescrire's Spotlight
Free >